Chronic verapamil administration lowers portal pressure and improves hepatic function in rats with liver cirrhosis.
The effects of verapamil on portal pressure, microsomal liver function and extravascular albumin space were investigated in rats rendered cirrhotic by chronic exposure to phenobarbital and carbon tetrachloride. Verapamil significantly decreased splenic pulp pressure by 28% (P less than 0.05). In cirrhotic animals it improved liver function, measured by the aminopyrine and caffeine breath tests, by 36% (P less than 0.025) and 53% (P less than 0.05), respectively. The extravascular albumin space, an important determinant of drug clearance, was measured by a multiple indicator dilution technique. It was significantly larger in verapamil treated than in untreated cirrhotics (4.41 +/- 1.06 vs 2.73 +/- 0.79 ml/g; P less than 0.01). We conclude that verapamil has significant potential as a portal antihypertensive agent and its value in treating cirrhosis in man should be explored by controlled studies.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006975:Hypertension, Portal / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy*; D008111:Liver Function Tests; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains; D014700:Verapamil / Q000627:therapeutic use*
D014700:Verapamil